IPG7236 with Toripalimab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with an advanced solid tumor that has spread or cannot be removed.
- Standard treatments must have failed, not exist, or not be suitable for you.
- You must have a tumor that can be measured on scans (like CT or MRI).
- Your overall health must be good (ECOG score 0 or 1), meaning you can do most daily activities.
- You must have adequate blood cell counts, kidney, liver, and clotting function (your doctor will test this).
- You cannot have had certain other cancer treatments or a CCR8-targeted therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (LM-108) combined with an existing immunotherapy (toripalimab) for people with advanced cancers that have a specific genetic feature (MSI-H or dMMR). The goal is to see if this combination can help when previous immunotherapy hasn't worked.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This study tests a new drug combo (CHS-114 + toripalimab) for people with advanced solid tumors like stomach, esophageal, or colorectal cancer that have already been treated. It aims to see if adding these drugs can help control the cancer better.
This trial tests a new drug called IPG1094 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
This study tests a new drug called LM-168, either alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that haven't responded to standard treatments. It aims to see if this combination is safe and effective, and may offer a new option when others have stopped working.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.